An interventional study of Scleral lenses treated with Tangible Hydra-PEG and Untreated scleral lenses in Dry Eye and Dry Eye Syndromes, sponsored by Tangible Science. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by Tangible Science · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 393rd largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2018, is one of 136 with no phase, and was the 256th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 36 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
Tangible Science is the lead sponsor of 3 studies on the registry; none are open to participants now.
Tangible Science has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population.
Dry eye (DE) is a common complaint of millions of people worldwide with a significant impact on quality of life. For decades, this condition has presented a challenge to eye care professionals as conventional therapies are often ineffective. Recently, scleral lenses have demonstrated to be a promising therapeutic and vision rehabilitative option for dry eye sufferers. Nonetheless, despite the benefits of scleral lenses for dry eye patients, inadequate wettability of scleral lenses with subsequent diminished comfort and visual clarity remains a concern for scleral lens wearers with dry eye.
Tangible Hydra-PEG (Tangible Science LLC, Menlo Park, CA, USA) is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time, ultimately enhancing contact lens comfort. While studies have shown that Tangible Hydra-PEG technology can improve contact lens discomfort (CLD) in soft contact lens and gas permeable lens wearers, to our knowledge, no clinical research investigation has examined the benefits of this new coating on scleral lens wear in dry eye sufferers. As such, the aim of this study is to compare the CLD and DE symptoms of dry eye scleral lens wearers between Tangible Hydra-PEG treated scleral lens wear and untreated scleral lens wear. CLD and DE signs will also be assessed to corroborate our findings.
This will be the first randomized double masked cross-over study to examine CLD and DE symptoms of Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population. Tangible Hydra-PEG treated scleral lenses can potentially minimize CLD and DE symptoms, ultimately improving outcomes for patients coping with dry eye disease. This study will provide new information about this innovative technology and help practitioners envisage rehabilitative options which will best optimize the quality of life of this important patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
Device: Scleral lenses treated with Tangible Hydra-PEG · Device: Untreated scleral lenses
Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
Device: Scleral lenses treated with Tangible Hydra-PEG · Device: Untreated scleral lenses
Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
Also known as: Tangible Hydra-PEG is a hydrophilic PEG-based lens coating
Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
Also known as: control
Ocular Surface Tear Breakup Time
Tear breakup time of the ocular surface after wearing lenses
Time frame: 30 days
Corneal Fluorescein Staining
Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses
Time frame: 30 days
Ocular Surface Disease Index (OSDI) Questionnaire
Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).
Time frame: 30 days
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.
Time frame: 30 days
Tear Breakup Time Over the Surface of the Scleral Lens
Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens
Time frame: 30 days
Lid Wiper Epitheliopathy
Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.
Time frame: 30 days
Contact Lens-related Papillary Conjunctivitis
Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis \[0 (normal) to 4 (severe)\] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.
Time frame: 30 days
Temporal Conjunctival Lissamine Green Staining
Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).
Time frame: 30 days
Nasal Conjunctival Lissamine Green Staining
Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).
Time frame: 30 days
| Milestone | Hydra-PEG Treated Lenses Followed by Untreated Lenses | Untreated Lenses Followed by Hydra-PEG Treated Lenses |
|---|---|---|
| Started | 9 | 12 |
| Completed | 8 | 11 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Milestone | Hydra-PEG Treated Lenses Followed by Untreated Lenses | Untreated Lenses Followed by Hydra-PEG Treated Lenses |
|---|---|---|
| Started | 8 | 11 |
| Completed | 8 | 11 |
| Not completed | 0 | 0 |
| Milestone | Hydra-PEG Treated Lenses Followed by Untreated Lenses | Untreated Lenses Followed by Hydra-PEG Treated Lenses |
|---|---|---|
| Started | 8 | 11 |
| Completed | 8 | 11 |
| Not completed | 0 | 0 |
Tear breakup time of the ocular surface after wearing lenses
| seconds | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Ocular Surface Tear Breakup Time | 3.81 ± 2.63 | 2.91 ± 2.14 |
Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses
| score on a scale | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Corneal Fluorescein Staining | 0.92 ± 0.79 | 1.40 ± 1.05 |
Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).
| OSDI score | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Ocular Surface Disease Index (OSDI) Questionnaire | 28.24 ± 12.90 | 35.10 ± 17.60 |
Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.
| CLDEQ-8 score | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) | 11.89 ± 5.26 | 17.30 ± 6.50 |
Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens
| seconds | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Tear Breakup Time Over the Surface of the Scleral Lens | 5.88 ± 5.17 | 4.75 ± 2.82 |
Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.
| score on a scale | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Lid Wiper Epitheliopathy | 0.89 ± 0.76 | 1.41 ± 0.62 |
Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis \[0 (normal) to 4 (severe)\] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.
| score on a scale | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Contact Lens-related Papillary Conjunctivitis | 0.89 ± 0.66 | 1.45 ± 0.51 |
Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).
| score on a scale | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Temporal Conjunctival Lissamine Green Staining | 0.95 ± 0.79 | 1.23 ± 1.03 |
Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).
| score on a scale | Hydra-PEG Treated Lens Wearers | Untreated Lens Wearers |
|---|---|---|
| Nasal Conjunctival Lissamine Green Staining | 0.79 ± 0.71 | 1.03 ± 0.98 |
Collected over Adverse event data were collected throughout the period of the study (a period of 79 days for each participant).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hydra-PEG Treated Lenses Followed by Untreated Lenses | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Untreated Lenses Followed by Hydra-PEG Treated Lenses | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
All participants wore both the Hydra-PEG treated and untreated lenses in this crossover study, therefore the baseline characteristics are the same for both lens types.
| Age, Continuous(years) | Participants |
|---|---|
| Mean | 51.8 ± 8 |
| Sex: Female, Male(Participants) | Participants |
|---|---|
| Female | 16 |
| Male | 3 |
| Race and Ethnicity Not Collected(Participants) | Participants |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Jan 2019, 11 months.
Results were first posted in Jan 2020, 1 year after primary completion.
Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 11 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.